Corporate$ARCT4:01 PM ETdeveloping · v2

Arcturus Therapeutics reports interim Phase 2 results for OTC deficiency, unveils LUNAR 2.0 platform

By BORSA NewsroomPublished Sep 23, 2026, 4:01 PM EDTUpdated Sep 25, 2026, 11:53 AM EDT

ARCT-810 showed safety and biomarker improvements in OTC deficiency. LUNAR 2.0 platform demonstrated >30-fold protein expression improvement in NHP studies. Company plans to integrate ARCT-2601 into Phase 2 study by year-end. Also acquiring AI discovery company myNEO.

Sentimentbullish 70

Bullish · 70 of 100

Impact70

medium · sector-wide

Confidence90%

high confidence · 2 wires

Eventdeveloping

v2 · alerts feed only

WHAT WE KNOW

ARCT-810 interim Phase 2: safe, well tolerated, reduced/maintained fasting ammonia, reduced glutamine, weight gain.